longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

TG Therap

TGTX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 19.72, above the reasonable range, cheaper than 16.15% of the time in the past 1 years, and the industry ranks 39/601, the industry Median -2.44.

19.72xP/E
$56.87Stock price
$2.88Earnings per share
19.72xP/E
Stock price$56.87Earnings per share$2.88

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
13.08x
Typical range
10.31x–19.30x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
AMGNUSAmgen
23.85x10.95%$208.49B
VRTXUSVertex Pharma
29.25x36.49%$128.84B
REGNUSRegeneron Pharma
18.67x4.10%$80.80B
INCYUSIncyte
15.75x65.04%$25.40B
GMABUSGenmab A/S
27.11x24.93%$21.36B
UTHRUSUnited Therap
16.18x6.53%$21.22B
ASNDUSAscendis Pharmac
18.08x477.31%$15.57B
NBIXUSNeurocrine Biosciences
21.07x50.66%$14.86B
EXELUSExelixis
16.80x16.46%$14.46B
TGTXUSTG Therap
19.72x65.83%$8.71B
VCYTUSVeracyte
27.94x35.02%$3.20B
CDNAUSCaredex
25.09x629.58%$2.78B
MGTXUSMeiraGTx
16.11x122.03%$1.27B
KMDAUSKamada
22.95x39.29%$510.74M
PBYIUSPuma BioTech
18.55x37.70%$495.55M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.